Medical Condition News

RSS

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

Potential new drug for treatment of MS to be presented at AAN Annual Meeting

Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology Annual Meeting, including a potential new drug for the treatment of multiple sclerosis and surprising trends showing a reduction in the disease's severity. The meeting will take place April 10-17 in Toronto.

15 Apr 2010

Researchers identify new strategy for treating acute myeloid leukemia

Researchers have identified a self-feeding "vicious circle" of molecules that keeps acute leukemia cells alive and growing and that drives the disease forward.

15 Apr 2010

Study combines CT and VBM to provide accurate picture of autistic brain

A new study, the first of its kind, combines two complementary analytical brain imaging techniques, to provide a more comprehensive and accurate picture of the neuroanatomy of the autistic brain. The study, published in the April issue of neuroimaging journal Human Brain Mapping, was conducted by researchers at The Montreal Neurological Institute and Hospital - The Neuro, McGill University and the Universit- de Montr-al.

15 Apr 2010

John Muir Physician Network to participate in Generex Oral-lyn FDA Expanded Access Treatment IND program

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that John Muir Physician Network Clinical Research Center has agreed to participate in the United States Food and Drug Administration (FDA) Expanded Access Treatment Investigational New Drug (IND) Program for the Company's flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product.

15 Apr 2010

Study provides support for relationship between APOE4 gene and risk of Alzheimer's disease in Latinos

A brain-imaging study published today in the Archives of Neurology suggests that a major genetic risk factor for Alzheimer's disease in the Anglo population is also a risk factor for the disease in Latinos.

15 Apr 2010

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

An investigational intervention using naturally ocurring antibodies in human blood has preserved the thinking abilities of a group of mild- to moderate-stage Alzheimer's patients over 18 months and significantly reduced the rate of atrophy (shrinkage) of their brains, according to a study performed at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

15 Apr 2010

Comparing effectiveness of PET and other molecular imaging techniques: SNM receives $48,000 AHRQ grant

SNM has been awarded a $48,000 grant from the Agency for Healthcare Research and Quality (AHRQ) to hold a conference to develop research on the comparative effectiveness of positron emission tomography (PET) and other molecular imaging techniques. The primary emphasis will be on the diagnosis and management of cancer patients, but both cardiology and neurology questions will also be addressed.

15 Apr 2010

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc. today announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis.

15 Apr 2010

Infliximab-azathioprine combination helps more Crohn's disease patients achieve remission

A study led by Mayo Clinic suggests remission from Crohn's disease may be more likely if patients get biologic therapy combined with immune-suppressing drugs first instead of immune-suppressing drugs alone. The study, published in the April 15, 2010 issue of the New England Journal of Medicine, found treatment of moderate to severe Crohn's disease with infliximab plus azathioprine allows more patients to achieve remission and mucosal healing than therapy with azathioprine alone.

15 Apr 2010

Successful stem cell therapy performed on CHF patients in Mexico

Bioheart, Inc. announced that treatment with stem cell therapy on two congestive heart failure (CHF) patients was performed successfully at the Hospital Angeles Tijuana, Mexico, through Bioheart's Center of Excellence program with Regenerative Medicine Institute.

15 Apr 2010

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma.

15 Apr 2010

Fathers of sexually abused children suffer from anxiety, grief and depression, says study

The preliminary results of a Universit- de Montr-al study show that fathers of sexually abused children can suffer from anxiety, depression and grief. Such patriarchs are often overwhelmed by a desire for vengeance, yet little literature exists to help them deal with their pain.

15 Apr 2010

Research report focuses on key influencers within employer health care market

Health Industries Research Companies' Employer & Coalition Service has released its spring 2010 market research. HIRC finds that employers are increasingly concerned about cancer medications and report sustained interest in health, wellness, and disease management initiatives.

15 Apr 2010

EGEE User Forum to highlight role of grid computing techniques in diagnosing cancer and heart diseases

Cancer, heart and circulatory system diseases cause two thirds of all deaths in Europe. Three research projects at this week's Enabling Grids for E-sciencE (EGEE) User Forum in Uppsala, Sweden, are demonstrating ways that modern computing techniques can investigate today's biggest killers.

15 Apr 2010

FDA: Seven MDIs for treating asthma and COPD to be phased out

The U.S. Food and Drug Administration today announced, in accordance with longstanding U.S. obligations under the Montreal Protocol on Substances that Deplete the Ozone Layer, seven metered-dose inhalers (MDI) used to treat asthma and chronic obstructive pulmonary disease (COPD) will be gradually removed from the U.S. marketplace. These inhalers contain ozone-depleting chlorofluorocarbons (CFCs), which are propellants that move medication out of the inhaler and into the lungs of patients.

15 Apr 2010

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.

15 Apr 2010

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

“Glucocorticoids are a key component of combination therapy regimens in multiple myeloma and other hematological cancers. However, glucocorticoid use comes with substantial dose limiting toxicities. The ability to enhance glucocorticoid dependent effects while sparing associated toxicities may have important implications for the treatment of multiple myeloma and other B-cell malignancies”

15 Apr 2010

Opexa Therapeutics presents key efficacy data on Tovaxin

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company presented key efficacy data at the American Academy of Neurology 62nd Annual Meeting held in Toronto, Canada.

15 Apr 2010

ICGC: New era of personalised medicine for cancer patients

Published online today in Nature, a paper authored by over 200 members of the International Cancer Genome Consortium describes the beginnings of a Brave New World, a new era of personalised medicine for cancer patients.

15 Apr 2010

Medical Condition News

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Potential new drug for treatment of MS to be presented at AAN Annual Meeting

Researchers identify new strategy for treating acute myeloid leukemia

Study combines CT and VBM to provide accurate picture of autistic brain

John Muir Physician Network to participate in Generex Oral-lyn FDA Expanded Access Treatment IND program

Study provides support for relationship between APOE4 gene and risk of Alzheimer's disease in Latinos

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

Comparing effectiveness of PET and other molecular imaging techniques: SNM receives $48,000 AHRQ grant

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

Infliximab-azathioprine combination helps more Crohn's disease patients achieve remission

Successful stem cell therapy performed on CHF patients in Mexico

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Fathers of sexually abused children suffer from anxiety, grief and depression, says study

Research report focuses on key influencers within employer health care market

EGEE User Forum to highlight role of grid computing techniques in diagnosing cancer and heart diseases

FDA: Seven MDIs for treating asthma and COPD to be phased out

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

Opexa Therapeutics presents key efficacy data on Tovaxin

ICGC: New era of personalised medicine for cancer patients

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News